The trajectory of Sildenafil presents a challenging picture for investors. While the initial launch generated significant returns, the expiration of its exclusive rights opened the floodgates to off-brand alternatives, https://mysitesname.com/story11595209/sildenafil-and-pharma-a-volatile-investment